Joseph J. Basile
Board Member
iSpecimen Inc. (ISPC)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Joseph J. Basile
Joseph J. Basile is recorded as Board Member at iSpecimen Inc. (ISPC). iSpecimen Inc. reported in an 8-K filed March 26, 2024 that Joseph J. Basile resigned as member of the Board of Directors of the Company, effective December 31, 2023. iSpecimen Inc. reported in an 8-K filed December 21, 2023 that Joseph J. Basile resigned as member of the Board of Directors, effective December 31, 2023. iSpecimen Inc. reported in an 8-K filed November 28, 2022 that Joseph J. Basile was appointed member of the Board and a member of each of the audit committee and nominating and corporate governance committee, effective November 28, 2022.
“the Company received a letter of resignation, on December 15, 2023, from Joseph J. Basile to resign as a member of the Board of Directors of the Company (the "Board"), effective December 31, 2023.”
“On December 15, 2023, iSpecimen Inc. (the "Company") received a letter of resignation from Joseph J. Basile to resign as a member of the Board of Directors of the Company (the "Board"), effective December 31, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-11-28–present
-
Start not stated–2023-12-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at iSpecimen Inc.
Other people whose current roles at this company are on record from its filings.
- Katharyn Field CEO
- Robert Bradley Lim CEO, Board Member
- Shahin Behroyan CEO
- Tracy Curley CEO, Board Member
- Andrew L. Ross Chairman
- Katherine (Katie) Field Chairman, Board Member
- Richard Paolone Chairman, Board Member
- Yuying Liang CFO
- Anthony Lau Board Member
- Arphing (Tommy) Lee Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.